Drug Database
Back to search

Poland· PL-100126583

Apidra

A insulin glulisine product containing insulinum glulisinum, registered in Poland by Sanofi-Aventis Deutschland GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC A10AB06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedApidraATCA10AB06REGISTER NO.PL-100126583PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulinum glulisinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin glulisine is registered in 14 of 19 countries.

Countries holding a registration under ATC A10AB06 (insulin glulisine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search insulin glulisine products by name

Insulin glulisine · ATC A10AB06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Insulinum glulisinum
Manufacturer
Sanofi-Aventis Deutschland GmbH
Country
Poland (PL)
ATC code
A10AB06
ATC class
Insulin glulisine
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

1 priced
  • gtin
    05909990008483
    1 fiol.po 10 ml
    PLN 85.67
  • gtin
    05909990005871
  • gtin
    05909990008490
  • gtin
    05909990008506
  • gtin
    05909990008537

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for insulin glulisine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin glulisine against other medicinesHow interaction checks work

Insulin glulisine · interactions on record

434 records

  • 15 severe
  • 368 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin glulisine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glulisine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Apidra, Apidra Solostar
  • Liechtenstein · Apidra, Apidra Solostar
  • Norway · Apidra, Apidra Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/87fd4eeb-1461-419d-a50c-a6b2022de8af
GET /v1/drugs/87fd4eeb-1461-419d-a50c-a6b2022de8af?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "100 j.m./ml",
  "packaging": "05909990005871 ¦ Rp ¦ Skasowane ¦ EU/1/04/285/001 ¦ 18944\n1 fiol. 10 ml\n05909990008483 ¦ Rp ¦ EU/1/04/285/001 ¦ 107768\n1 fiol. 10 ml\n05909990008490 ¦ Rp ¦ EU/1/04/285/002 ¦ 107769\n2 fiol. 10 ml\n05909990008506 ¦ Rp ¦ EU/1/04/285/003 ¦ 107770\n4 fiol. 10 ml\n05909990008537 ¦ Rp ¦ EU/1/04/285/004 ¦ 107771\n5 fiol. 10 ml",
  "substance": "Insulinum glulisinum 100 j.m./1 ml",
  "common_name": "Insulinum glulisinum",
  "pl_product_id": "100126583",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about insulin glulisine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console